● LIVE #ESMO26 live from Madrid, Oct 23–27 — today’s highlights, trending trials and physician reactions Follow ESMO 2026 live →
KOL Pulse Insights Blog

Oncology KOL Intelligence, decoded.

Key opinion leader trends, clinical-trial commentary, conference recaps, and AI-native intelligence on the physicians shaping oncology practice — straight from the social conversation.

2Articles
WeeklyNew insights
500+Verified oncologists tracked
0 articles · All topics
ENERGIZE and KEYNOTE-866: Two Negative Phase 3 MIBC Trials at ESMO 2026, and the NIAGARA Question
Oct 24, 2026, 2:32:23 AM Brian Shields

ENERGIZE and KEYNOTE-866: Two Negative Phase 3 MIBC Trials at ESMO 2026, and the NIAGARA Question

ESMO 2026: perioperative nivolumab (ENERGIZE, EFS HR 0.94) and pembrolizumab (KEYNOTE-866, EFS HR 0.88, OS HR 1.00) with gem/cis did not improve EFS in cisplati…

mibckol reactionsesmo 2026
NIAGARA Trial : FDA Approval Launch Pack for Clinicians
Mar 29, 2025, 6:40:06 AM Brian Shields

NIAGARA Trial : FDA Approval Launch Pack for Clinicians

Key Opinion Leaders in GU Oncology have provided a plethora of resources to help clinicians process the recent FDA approval of durvalumab for MIBC based on the …

NIAGARAmibcdurvalumab

Track the KOLs shaping oncology

KOL Pulse turns the oncology social conversation into AI-native intelligence. See it in action.

Book a Demo Back to Homepage